On August 5, 2025, PTC Therapeutics, Inc. entered into a Rights Satisfaction Agreement that cancels payments owed to former Censa Pharmaceuticals securityholders based on net sales, paying approximately $225 million upfront and potential future milestone payments based on sales thresholds. This agreement does not alter the other terms of the original merger agreement made in 2020.